Bluvial 4mg Vial Of 3ml Injection
3ml Injection in VialMRP ₹1295.00
₹1165.50
10% OFF
Made by
ERIS LIFE SCIENCES PVT LTD
Dosage
INJECTION
Expiry
Product Summary
| Salt Content | Semaglutide(4.0 Mg/3ml) |
| Uses | Risk reduction of major cardiovascular events and management of obesity |
| Therapy | Anti-obesity, anti-diabetic |
| Side effects | Nausea, diarrhea, vomiting, constipation, and headache |
Assurance
available
Regulated
Medical Description
Bluvial injection is a prescription medication used alongside a reduced-calorie diet and increased physical activity for long-term weight management. It is indicated for adults and adolescents (12+) with obesity, and for adults with overweight who have at least one weight-related health condition. For adults with known cardiovascular disease and either obesity or overweight, it also helps reduce the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke).
This injection contains semaglutide as its active ingredient, which mimics the natural hormone GLP-1 to help regulate appetite and food intake. It activates GLP-1 receptors in the brain that help you feel full, reducing hunger and calorie intake.
Bluvial injection is administered once weekly, on the same day each week, at any time of day, with or without meals, by subcutaneous injection in the abdomen, thigh, or upper arm.
Bluvial injection should not be used by people who have a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC) or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Uses
- Reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease and either obesity or overweight.
- Reducing excess body weight and maintaining long-term weight loss through a low-calorie diet and exercise in adults, as well as in patients aged 12 years and over with obesity, and in adults with overweight who have at least one weight-related comorbid condition.
Contraindications
- Bluvial injection is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- A known allergy to semaglutide or any of the excipients in Bluvial injection.
Side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dyspepsia
- Dizziness
- Abdominal distension
- Eructation (belching)
- Hypoglycemia (low blood sugar) in patients with type 2 diabetes
- Flatulence (gas)
- Gastroenteritis
- Gastroesophageal reflux disease (GERD)
- Nasopharyngitis (runny nose or sore throat)
- Possible thyroid tumours, including cancer: Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
- Inflammation of the pancreas (pancreatitis): Stop using Bluvial injection and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting.
- Gallbladder problems: Bluvial injection may cause gallbladder issues, including the formation of gallstones. Some gallbladder problems need surgery. Call your healthcare provider if you experience symptoms such as upper stomach pain, fever, yellowing of the skin or eyes (jaundice), or clay-coloured stools.
- Increased risk of low blood sugar (hypoglycemia): Especially in those who also take medicines to treat type 2 diabetes.
- Kidney problems (kidney failure): In people who have kidney problems, diarrhoea, nausea, and vomiting may cause a loss of fluids (dehydration,) which may cause kidney problems to get worse.
- Serious allergic reactions: Stop using Bluvial injection and seek medical help immediately if you experience any symptoms of a serious allergic reaction, including swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe rash or itching; dizziness, fainting, or a rapid heartbeat.
- Change in vision in people with type 2 diabetes.
- Increased heart rate.
- Depression or thoughts of suicide.
Precautions and Warnings
Pregnancy
Breast Feeding
Driving
Alcohol
Other General Warnings
- You have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You experience symptoms of thyroid tumors (e.g., a mass in the neck, difficulty swallowing, difficulty breathing, persistent hoarseness).
- You experience persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting (symptoms of acute pancreatitis).
- You experience symptoms of gallbladder disease, such as cholelithiasis or cholecystitis.
- You have diabetes and experience signs or symptoms of hypoglycemia (low blood sugar), especially if you are taking insulin or a sulfonylurea.
- You experience severe gastrointestinal reactions (nausea, vomiting, or diarrhea) that could lead to dehydration.
- You have kidney impairment and experience any adverse reactions that could lead to volume depletion.
- You experience signs or symptoms of a serious allergic reaction (e.g., anaphylaxis, angioedema).
- You have a history of diabetic retinopathy.
- You experience palpitations or a racing heartbeat at rest.
- You experience the emergence or worsening of depression, suicidal thoughts or behaviour, and/or any unusual changes in mood or behaviour.
- You have a history of suicidal attempts or active suicidal ideation.
- You planning any elective surgeries or procedures requiring general anaesthesia or deep sedation?
Directions for Use
- Your healthcare provider should show you how to use the pen before your first use.
- Bluvial injection is injected subcutaneously (under the skin) in the stomach (abdomen), thigh, or upper arm.
- It is used once a week, on the same day each week, at any time of the day.
- The day of weekly administration can be changed if necessary, as long as the last dose was given at least 2 days earlier.
- Bluvial injection should be visually inspected before each use to ensure the solution is clear, colourless, and free from particles.
- Rotate the injection site with each injection.
Storage and disposal
- Store the Bluvial injection in the refrigerator between 2°C to 8°C.
- If needed, the pen can be stored at room temperature between 8°C and 30°C for up to 28 days before removal of the cap.
- Do not freeze Bluvial injection.
- Keep Bluvial in the original carton to protect it from light.
Quick Tips
- Bluvial is a once-weekly injection. Always administer it on the same day each week, and carefully follow your doctor's prescribed dose increase schedule to minimise side effects. Do not raise your dose faster than advised.
- Learn to use the FlexTouch pen correctly from your healthcare provider. Inject subcutaneously (just under the skin) into your stomach, thigh, or upper arm, rotating injection sites weekly.
- Bluvial works best when combined with a reduced-calorie diet and increased physical activity. Focus on maintaining consistent, healthy eating habits and engaging in regular physical activity for optimal health and well-being.
- Nausea, vomiting, diarrhoea, and constipation are common, especially when beginning treatment. Drink plenty of fluids to prevent dehydration. If side effects are severe or persistent, contact your doctor immediately. Eating smaller meals, avoiding greasy foods, and staying hydrated can help.
- Be aware of signs of serious side effects like severe abdominal pain (pancreatitis), symptoms of gallbladder issues, severe allergic reactions, or changes in mood/thoughts (e.g., depression, suicidal ideation). Report any concerning symptoms to your doctor straight away.
- Keep your healthcare provider informed about all medications you're taking, any new or worsening health conditions, and how you're feeling while taking Bluvial injection. Regular follow-ups are crucial for monitoring your progress and addressing any potential issues.
Dosage
Overdose
Missed a Dose
- If you miss a dose and the next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as possible.
- If you miss a dose and the next scheduled dose is less than 2 days (48 hours) away, do not take the missed dose. Take your next dose on your regularly scheduled day.
- If you miss 2 or more consecutive doses, take your next dose as scheduled or contact your healthcare provider for instructions on how to restart your treatment.
Mode of Action
How Does It Work?
Interactions
Interactions with other medicines
- Bluvial injection can slow stomach emptying, which may affect the absorption of certain oral medications.
- The risk of hypoglycemia is increased when Bluvial injection is used with insulin or insulin secretagogues (e.g., sulfonylureas). A lower dose of insulin or the insulin secretagogue may be needed.
- It is not recommended to use Bluvial injection with other semaglutide-containing products or other GLP-1 receptor agonists.
Frequently Asked Questions (FAQs)
Articles
View AllChronic Condition Articles
View AllDid you find this helpful?
Explore More at Pharmeasy
Manufacturer Details
Brand:BLUVIAL
Manufacturer Name:ERIS LIFE SCIENCES PVT LTD
Address:NATCO PHARMA LIMITED Vijayapuri North (V), Peddavoora (M), Nalgonda (D), Nagarjunasagar-508 202. Regd. Office: NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad-500034
Country of Origin:India
Vendor Details
Fulfillment Information: Bluvial 4 MG/3ML Injection (3) will be delivered by a licensed retail pharmacy nearest to your location. Order acceptance and fulfillment are dependent upon the verification of your doctor's valid prescription (where applicable) and the current stock of this medicine.
References:
- Wegovy. Official Site. Wegovy.com [Internet]. [Accessed 28 Jun 2025].
- Wegovy® (semaglutide) injection prescribing information. Novo Nordisk [Internet]. [Accessed 28 Jun 2025].
- Wegovy: Product information for healthcare professionals. NovoMedLink [Internet]. [Accessed 28 Jun 2025].
- Summary of Product Characteristics for Wegovy. Electronic Medicines Compendium (EMC) [Internet]. [Accessed 28 Jun 2025].
- Central Drugs Standard Control Organisation (CDSCO). Drugs Information Portal [Internet]. [Accessed 28 Jun 2025].
In Case of Any Issues Contact Us
Email Id:care@pharmeasy.in
Phone Number:7666100300
Address:D-37/1, Opp. Sandoz, TTC Industrial Area, MIDC Industrial Area, Turbhe, Navi Mumbai, Maharashtra 400703
Disclaimer
The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. You should not use the information provided herein to diagnose, prevent, or cure a health problem. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation. The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition. You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. Please click here for detailed T&C.



















